EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Innovation Management at Bachem
Chief Technology Officer, Bachem Holding AG
Gnther Loidl joined Bachem in He held several functions in Research and Development RD and Active Pharmaceutical Ingredient Manufacturing and became Vice President RD in Since he is CTO of the Bachem Group and a member of the Corporate Executive Committee He studied chemistry in Regensburg Germany and Leeds UK and obtained his doctorate under the supervision of Luis Moroder at the Max Planck In...
Articles
Novel Claudin Targeted C-terminal Clostridium Perfringens Enterotoxin Conjugated Anticancer Nanotherapeutics
Active targeting with nanomedicines can result in effective drug delivery to targeted cells maximising therapeutic efficacy while decreasing systemic side effects The main application of this approach is paying attention toward cancer therapy Cancer threats were found in worldwide population due to increasing adoption of cancercausing behaviors
Research Insights
Brain High-throughput Multi-omics Data Reveal Molecular Heterogeneity in Alzheimer’s Disease
Alzheimer disease is a heterogeneous multifactorial neurodegenerative disorder pathologically characterized by amyloid plaques neurofibrillary tangles neuroinflammation and synaptic and neuronal loss
Case Studies
Remarkable Regression Of A Giant Cell Tumor Of The Cervical Spinetreated Conservatively With Denosumab: A Case Study
Abstract This case study has been conducted to establish the fact that Denosumab can be used as an adjuvant therapy by which to avoid or reduce the risks and morbidity of surgical treatment in patients with spinal GCTs extending into the nearby tissues considering the adequate duration safety and lack of adverse events of this treatment even though further
Techno Trends
UCB Introduces Breakthrough CIMZIA Therapy for Treating Antiphospholipid Syndrome
UCB has introduced CIMZIA certolizumab pegol for the prevention of placentamediated adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome APS a rare autoimmune disorder
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Rapidly Evolving Landscape of Cancer Therapeutics
Rajesh Kumar is an Assistant Professor of Pharmaceutical Sciences at Kerala University of Health Sciences, India. He has been teaching Diploma, Bachelor, and Doctor of Pharmacy students for several years and is actively involved in research. He has authored more than 19 papers and is a reviewer for Bentham Science Publishers. His research includes applying the principles of pharmaceutical sciences, omics technologies, computational biology, and bioinformatics in the broad areas of cancer research, ethnopharmacology, drug delivery, targeting, and formulations.
Seetha Harilal is an Assistant Professor of Pharmacology at Kerala University of Health Sciences, India. She has several years of experience in teaching Diploma, Bachelor, and Doctor of Pharmacy students and is actively pursuing research. She has authored more than 22 papers and is a manuscript reviewer for Bentham Science Publishers, Frontiers in Public Health, Frontiers in Medicine, and Archives of Medical Research (Elsevier). Her research includes the diverse areas of pharmacology and therapeutics, phytopharmaceuticals, cancer research, neurological disorders, and the application of omics technologies, computational pharmacology, and bioinformatics.
Nanotechnology Strategies for Age –Related Macular Degeneration
Aira Sarkar is pursuing B. Tech (Pharmaceutical Chemistry and Technology) in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).
Sathish Dyawanapelly is working as an Assistant Professor in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).
Repurposed Drugs against the Latest Variants of Concerns of SARS-CoV-2
Sinosh Skariyachan Ph.D. is presently working as Assistant Professor in Microbiology at St. Pius X College, Rajapuram (Aided by Govt. of Kerala, India), Kasaragod, Kerala, India with more than 17 years of experience in teaching and research. One of his key areas of research is computational drug discovery and medicinal chemistry. He has published more than 75 international papers, book chapters, and text books. He is the editor of prestigious journals such as Computers in Biology and Medicine (Elsevier), Frontiers in Microbiology and a referee for more than 125 international journals. He received several awards and grants.
Synbiotics in Metabolic Health
Dr. Neeraj Mishra is working as Professor and Head, Department of Pharmaceutics, in Amity Institute of Pharmacy, Gwalior since July 2019. He has around twenty years of teaching and research experience. He has more than 100 publications of International and National repute in recent concepts of novel drug delivery systems, localised drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders. Dr. Mishra more than 3700 citations with h- index 32. The total cumulative Impact Factor of his published papers is more than 300 (as per SCOPUS). He has also written 15 Books and 30 book chapters in Elsevier, Bentham, Springer and Wiley Publication etc. He has also been granted 3 international patents and 2 Indian patents. Dr. Mishra is recipient of “Distinguished Professor Award” 2019 from DST-NSTMIS, SPAICS, Indore, and M.P. in September 2019. Dr. Mishra has received the “Distinguished Professor Award '' 2021 from Indian Pharmaceutical Association, MP State Branch, Indore. Dr Mishra has received Best Academician Award in the Indian Pharmacy Graduate Association, M.P. State International Conference held on 06th May 2023 at DAVV Auditorium, Indore, India.
Dr. Devyani Rajput is working as an Assistant Professor, Department of Pharmacognosy, in Amity Institute of Pharmacy, Gwalior since Jan 2024. She has around seven years of research experience. Her expertise includes nanotechnology, phytomedicine, and advanced drug delivery systems, with notable contributions to cancer research. She has participated in various national and international conferences, published impactful research, and received prestigious awards, including the BEST SCHOLAR AWARD 2023. She has more than 150 citations with h- index 3. She has received the CSIR travel Grant in April 2024 for presenting her research work in Istanbul University.
Detangling the Diagnostic Odyssey in Neurodevelopmental Disorder by Genomic Consultancy
Emili is a well-known genetic consultant with vast experience in cytogenetics, molecular biology with special emphasis in neurobiology. She is doing human genetics for past 22 years and now is practising genetic counselling as well as continuing her passion for research.
Koutilya basically is an academician in Zoology and has research interest in areas like anti-microbial peptides of amphibians, bio-active components of amphibians and genetic aspects of human reproductive disorder.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement